How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
Andrew A. F. Hack, insider at Mersana Therapeutics

Andrew A. F. Hack Insider Information

Andrew A. F. Hack, M.D., Ph.D., has served as a member of our Board of Directors since January 2017. Since March 2019, Dr. Hack has served as a Managing Director of Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Before joining Bain Capital, Dr. Hack was the Chief Financial Officer of Editas Medicine from July 2015 through March 2019. Previously, Dr. Hack served as a portfolio manager at Millennium Management, where he ran a healthcare hedge fund focused on biotechnology, pharmaceutical and medical device companies from May 2011 to June 2015. Prior to Millennium, Andrew was an analyst at HealthCor Management from December 2008 to May 2011. Prior to HealthCor Management, Dr. Hack was an analyst at Carlyle-Blue Wave Partners and a principal of the MPM BioEquities Fund. He started his investment career as an equity research analyst covering the biotechnology sector at Banc of America Securities after serving as Director of Life Sciences at Reify Corporation, a life science tools and drug discovery company.

In addition, Dr. Hack has been a member of the Board of Directors of Allena Pharmaceuticals since June 2018, and serves as the Chair of its Audit Committee, and has been a member of the Board of Directors of Dynavax Technologies since August 2019, and serves as a member of its Audit Committee. Dr. Hack received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D. and was named the inaugural Frank Family Scholar.

What is Andrew A. F. Hack's net worth?

The estimated net worth of Andrew A. F. Hack is at least $28.23 million as of May 18th, 2022. Dr. Hack owns 8,087,400 shares of Mersana Therapeutics stock worth more than $28,225,026 as of May 22nd. This net worth estimate does not reflect any other investments that Dr. Hack may own. Learn More about Andrew A. F. Hack's net worth.

How do I contact Andrew A. F. Hack?

The corporate mailing address for Dr. Hack and other Mersana Therapeutics executives is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. Mersana Therapeutics can also be reached via phone at (617) 498-0020 and via email at [email protected] Learn More on Andrew A. F. Hack's contact information.

Has Andrew A. F. Hack been buying or selling shares of Mersana Therapeutics?

Over the course of the past ninety days, Andrew A. F. Hack has bought $3,627,152.48 in shares of Mersana Therapeutics stock. As far as recent transactions, on Sunday, May 22nd, 0 shares of BMO Capital Markets stock. Learn More on Andrew A. F. Hack's trading history.

Who are Mersana Therapeutics' active insiders?

Mersana Therapeutics' insider roster includes Lawrence Alleva (Director), Andrew Hack (Director), Timothy Lowinger (Insider), Ashish Mandelia (VP), Anna Protopapas (CEO), and Arvin Yang (Insider). Learn More on Mersana Therapeutics' active insiders.

Are insiders buying or selling shares of Mersana Therapeutics?

During the last twelve months, Mersana Therapeutics insiders bought shares 5 times. They purchased a total of 2,082,044 shares worth more than $8,664,760.24. During the last twelve months, insiders at the sold shares 10 times. They sold a total of 78,519 shares worth more than $860,510.75. The most recent insider tranaction occured on May, 18th when Director Andrew A F Hack bought 211,268 shares worth more than $707,747.80. Insiders at Mersana Therapeutics own 5.3 % of the company. Learn More about insider trades at Mersana Therapeutics.

Information on this page was last updated on 5/18/2022.

Andrew A. F. Hack Insider Trading History at Mersana Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2022Buy211,268$3.35$707,747.808,087,400View SEC Filing Icon  
5/16/2022Buy135,292$3.10$419,405.207,872,692View SEC Filing Icon  
4/12/2022Buy598,086$4.18$2,499,999.487,120,116View SEC Filing Icon  
2/7/2022Buy1,136,363$4.42$5,022,724.46View SEC Filing Icon  
1/12/2021Buy250,000$18.36$4,590,000.00View SEC Filing Icon  
1/8/2021Buy100,000$18.39$1,839,000.00View SEC Filing Icon  
4/7/2020Buy3,445,667$9.43$32,492,639.81538,599View SEC Filing Icon  
See Full Table

Andrew A. F. Hack Buying and Selling Activity at Mersana Therapeutics

This chart shows Andrew A F Hack's buying and selling at Mersana Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mersana Therapeutics Company Overview

Mersana Therapeutics logo
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.49
Low: $3.37
High: $3.63

50 Day Range

MA: $3.90
Low: $2.84
High: $4.91

2 Week Range

Now: $3.49
Low: $2.68
High: $15.34


1,453,409 shs

Average Volume

1,133,666 shs

Market Capitalization

$338.50 million

P/E Ratio


Dividend Yield



Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.